Agouron Pharmaceuticals, Inc.

Novo Nordisk A/s

Michael David Johnson

Min Teng

Christine Thomas

Michael Brennan Wallace

Siegfried Heinz Reich

Robert Steven Kania

Cynthia Louise Palmer

Michael D Varney

Steven Lee Bender

Michael Raymond Collins

Allen Borchardt

Theodore Otto Johnson, Jr

Stephan James Cripps

Hiep The Luu

Ye Hua

Dan Kiel

Jesper F Lau

Peter Madsen

Yufeng Hong

Vlad Edward Gregor

Anthony Lai Ling

Javier Gonzalez

Anna Maria Tempczyk-Russell

Larry Kenneth Truesdale

Atsuo Kuki

Anna Marie Tempczyk-Russell

Jun Feng

Preben H Olesen

Janos Tibor Kodra

Daljit Singh Dhanoa

Christian Klarner Sams

Carsten Behrens

Anker S Jorgensen

Michael Bruno Plewe

Lars Naerum

Dilip Ramakant Bhumralkar

Shenghua Shi

Liselotte Bjerre Knudsen

Ulla Grove Sidelmann

Ingrid Petterson

Lotte Bjerre Knudsen

Ranjan Jagath Rajapakse

Johannes Cornelis De Jong

Richard A Bychowski

Kimberly Ann Teston

Tso-sheng Chou

Indazole compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.

Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use

Novel non-peptide GLP-1 agonists, pharmaceutical compositions comprising them, use of the non-peptide GLP-1 agonists for the preparation of pharmaceutical compositions and methods for the treatment and/or prevention of disorders and diseases wherein an activation of the human GLP-1 receptor is beneficial, especially metabolic disorders such as IGT, Type 1 diabetes, Type 2 diabetes and obesity.

Non-peptide GLP-1 agonists

Indazole compounds and pharmaceutical compositions for Inhibiting protein kinases, and methods for their use

Non-peptide compounds comprising a central hydrazide motif and methods for the synthesis thereof are disclosed. The compounds act to antagonize the action of the glucagon peptide hormone.

Glucagon antagonists/inverse agonists

Non-peptide compounds that act as antagonists of the intestinal hormone glucagons-like peptide 1 (GLP-1) have a 9H-b-carboline central motif. The compounds exhibit advantageous physical, chemical and biological properties and inhibit GLP-1 peptide binding to the GLP-1 receptor and/or prevent activation of the receptor by bound GLP-1. The invention further relates to a method of inhibiting the binding of GLP-1 to the GLP-1 receptor and a method of inhibiting the activation of the GLP-1 receptor. Intermediate compounds useful for making non-peptide GLP-1 receptor antagonists are also described.

Non-peptide antagonists of GLP-1 receptor and methods of use

Growing community of inventors

San Diego, CA, United States of America

Michael David Johnson